MA35803B1 - Polypeptides d'interleukine-2 mutants - Google Patents
Polypeptides d'interleukine-2 mutantsInfo
- Publication number
- MA35803B1 MA35803B1 MA36237A MA36237A MA35803B1 MA 35803 B1 MA35803 B1 MA 35803B1 MA 36237 A MA36237 A MA 36237A MA 36237 A MA36237 A MA 36237A MA 35803 B1 MA35803 B1 MA 35803B1
- Authority
- MA
- Morocco
- Prior art keywords
- polypeptides
- immunoconjugates
- interleukin
- mutant polypeptides
- polynucleotide molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne d'une maniere generale des polypeptides d'interleukine-2 mutants qui presentent une affinite reduite a la sous-unite ± du recepteur il-2, que l'on utilise comme agents immunotherapeutiques. De plus, l'invention concerne des immunoconjugues comprenant lesdits polypeptides d'il-2, des molecules polynucleotidiques codant les polypeptides d'il-2 ou des immunoconjugues, et des vecteurs et cellules hotes comprenant de telles molecules polynucleotidiques. L'invention concerne enfin des procedes de production de polypeptides d'il-2 mutants ou des immunoconjugues, des compositions pharmaceutiques les comprenant, ainsi que leurs utilisations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11153964 | 2011-02-10 | ||
EP11164237 | 2011-04-29 | ||
PCT/EP2012/051991 WO2012107417A1 (fr) | 2011-02-10 | 2012-02-07 | Polypeptides d'interleukine-2 mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35803B1 true MA35803B1 (fr) | 2014-12-01 |
Family
ID=45560919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36237A MA35803B1 (fr) | 2011-02-10 | 2013-09-10 | Polypeptides d'interleukine-2 mutants |
Country Status (36)
Country | Link |
---|---|
US (5) | US9266938B2 (fr) |
EP (4) | EP2673294B1 (fr) |
JP (2) | JP5878182B2 (fr) |
KR (2) | KR101667096B1 (fr) |
CN (3) | CN112210000A (fr) |
AR (1) | AR085335A1 (fr) |
AU (2) | AU2012215573B2 (fr) |
BR (1) | BR112013018932B1 (fr) |
CA (1) | CA2824253C (fr) |
CL (1) | CL2013001987A1 (fr) |
CO (1) | CO6741186A2 (fr) |
CR (1) | CR20130314A (fr) |
CY (1) | CY1117842T1 (fr) |
DK (3) | DK3489255T3 (fr) |
EA (1) | EA033369B1 (fr) |
EC (1) | ECSP13012815A (fr) |
ES (3) | ES2579987T3 (fr) |
HK (1) | HK1217020A1 (fr) |
HR (3) | HRP20160917T1 (fr) |
HU (3) | HUE029139T2 (fr) |
IL (3) | IL269687B (fr) |
LT (2) | LT3075745T (fr) |
MA (1) | MA35803B1 (fr) |
MX (2) | MX340671B (fr) |
MY (1) | MY190604A (fr) |
PE (2) | PE20140303A1 (fr) |
PH (1) | PH12017500954A1 (fr) |
PL (3) | PL3075745T3 (fr) |
PT (3) | PT3075745T (fr) |
RS (3) | RS62238B1 (fr) |
SG (2) | SG10201604160WA (fr) |
SI (3) | SI3075745T1 (fr) |
TW (2) | TWI666027B (fr) |
UA (2) | UA117294C2 (fr) |
WO (1) | WO2012107417A1 (fr) |
ZA (1) | ZA201305282B (fr) |
Families Citing this family (242)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
NZ703653A (en) | 2010-08-13 | 2016-09-30 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
UA117294C2 (uk) | 2011-02-10 | 2018-07-10 | Рош Глікарт Аг | Імунокон'югат |
KR101981342B1 (ko) * | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP6175428B2 (ja) | 2011-06-01 | 2017-08-02 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 細菌のポリシストロン性発現系 |
WO2013026839A1 (fr) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
SG10201800535XA (en) * | 2012-08-07 | 2018-02-27 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US10087250B2 (en) | 2012-10-08 | 2018-10-02 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
CN104781279A (zh) * | 2012-11-30 | 2015-07-15 | 罗切格利卡特公司 | 利用包含癌细胞靶向性mhc i类的多功能蛋白通过循环中的病毒特异性细胞毒性t细胞清除癌细胞 |
PL2935328T3 (pl) | 2012-12-21 | 2019-02-28 | Hoffmann La Roche | Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP3620473A1 (fr) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Nouvelles protéines hétérodimères |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
KR102282761B1 (ko) * | 2013-02-26 | 2021-07-30 | 로슈 글리카트 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
CA2896370A1 (fr) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Molecules bispecifiques de liaison a l'antigene activant les lymphocytes t |
US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP2970486B1 (fr) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation de cellules t avec des anticorps bispecifiques et des fusions fc |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
PT3041854T (pt) | 2013-08-08 | 2020-03-05 | Scripps Research Inst | Um método para a identificação enzimática específica ao local de ácidos nucleicos in vitro pela incorporação de nucleótidos não-naturais |
SI3102595T1 (sl) | 2014-02-06 | 2019-02-28 | F. Hoffmann-La Roche Ag | Fuzijske beljakovine z interlevkinom-2 in njihova uporaba |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9822186B2 (en) | 2014-03-28 | 2017-11-21 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
TWI638047B (zh) | 2014-04-09 | 2018-10-11 | 史基普研究協會 | 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中 |
CN106604932A (zh) | 2014-07-10 | 2017-04-26 | 诺华公司 | 人白细胞介素‑2的免疫刺激单克隆抗体 |
IL289475B2 (en) * | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
EP3482766B1 (fr) * | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Variantes il-2 modifiées d'activation sélective de lymphocytes t régulateurs pour le traitement de maladies auto-immunes |
KR102058846B1 (ko) * | 2014-08-29 | 2020-02-20 | 에프. 호프만-라 로슈 아게 | 종양-표적 il-2 변이체 면역사이토카인 및 인간 pd-l1에 대한 항체의 조합 요법 |
CN113372434B (zh) | 2014-11-14 | 2024-06-04 | 豪夫迈·罗氏有限公司 | 包含tnf家族配体三聚体的抗原结合分子 |
SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
EP3789402B1 (fr) | 2014-11-20 | 2022-07-13 | F. Hoffmann-La Roche AG | Thérapie de combinaison de molécules de liaison à l'antigène bispécifiques d'activation des lymphocytes t et d'antagonistes de liaison à l'axe pd-1 |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
EA201791139A1 (ru) | 2014-11-26 | 2018-04-30 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10793613B2 (en) | 2014-12-15 | 2020-10-06 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2016105450A2 (fr) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Anticorps trispécifiques |
WO2016141387A1 (fr) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc |
EP3277305B1 (fr) | 2015-03-31 | 2021-07-21 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子 |
JP6622392B2 (ja) | 2015-10-02 | 2019-12-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pd1とtim3に特異的な二重特異性抗体 |
WO2017077382A1 (fr) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Protéines chimères bifonctionnelles et leurs utilisations |
AU2016362777B2 (en) | 2015-12-04 | 2020-01-30 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
EP3387013B1 (fr) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Anticorps hétérodimères se liant à cd3 et psma |
IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
EP3178848A1 (fr) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments |
WO2017106767A1 (fr) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production de nucléotides non naturels par l'utilisation d'un système crispr/cas9 |
MX2018008347A (es) | 2016-01-08 | 2018-12-06 | Hoffmann La Roche | Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3. |
CA3009001A1 (fr) | 2016-01-11 | 2017-07-20 | Universitat Zurich | Anticorps monoclonaux humainises immunostimulants diriges contre l'interleukine -2 humaine, et leurs proteines de fusion |
DK3402499T3 (da) | 2016-01-14 | 2021-09-27 | Intrexon Actobiotics Nv | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
AU2017213659B2 (en) | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
JP2019507762A (ja) | 2016-03-07 | 2019-03-22 | ブイアイビー ブイゼットダブリュー | Cd20結合単一ドメイン抗体 |
LT3433280T (lt) | 2016-03-22 | 2023-07-10 | F. Hoffmann-La Roche Ag | Proteazės aktyvuojamos t ląstelei bispecifinės molekulės |
WO2017194783A1 (fr) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Interféron bêta mutant ciblé, et utilisations associées |
WO2017194782A2 (fr) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Ciblage thérapeutique de structures non cellulaires |
RU2767357C2 (ru) | 2016-06-14 | 2022-03-17 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2017220990A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anticorps anti-pd-l1 |
WO2017223528A1 (fr) | 2016-06-24 | 2017-12-28 | The Scripps Research Institute | Nouveau transporteur de nucléoside triphosphate et ses utilisations |
WO2018005706A1 (fr) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN110087681A (zh) | 2016-09-28 | 2019-08-02 | 佐马美国有限公司 | 结合白细胞介素-2的抗体和其用途 |
EP3519437B1 (fr) | 2016-09-30 | 2021-09-08 | F. Hoffmann-La Roche AG | Anticorps bispécifiques dirigés contre p95her2 |
RU2019114175A (ru) | 2016-10-14 | 2020-11-16 | Ксенкор, Инк. | Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1 |
JP7213180B2 (ja) * | 2016-10-19 | 2023-01-26 | エフ.ホフマン-ラ ロシュ アーゲー | 免疫コンジュゲートを製造するための方法 |
CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
CN110167957A (zh) * | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
SI3558339T1 (sl) * | 2016-12-22 | 2024-05-31 | Cue Biopharma, Inc. | Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe |
CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
EP3576765A4 (fr) | 2017-02-06 | 2020-12-02 | Orionis Biosciences, Inc. | Interféron d'ingénierie ciblé et utilisations de ce dernier |
US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
WO2018170288A1 (fr) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Immunotolérance ciblée |
WO2018184965A1 (fr) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugués d'il-2 avec un anticorps bispécifique anti-pd-1 et tim-3 |
RS63663B1 (sr) | 2017-04-03 | 2022-11-30 | Hoffmann La Roche | Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15 |
RU2766234C2 (ru) * | 2017-04-04 | 2022-02-10 | Ф. Хоффманн-Ля Рош Аг | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap |
CA3052532A1 (fr) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Anticorps bispecifiques se liant particulierement a pd1 et lag3 |
EP3610006B1 (fr) * | 2017-04-11 | 2021-05-19 | Roche Diagnostics GmbH | Transcriptase inverse mutante présentant une meilleure stabilité thermique ainsi que des produits, procédés et utilisations l'impliquant |
CN110505883A (zh) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215936A1 (fr) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
EP3630162A1 (fr) * | 2017-05-24 | 2020-04-08 | Novartis AG | Protéines greffées anticorps-cytokine et méthodes d'utilisation |
WO2019006472A1 (fr) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
WO2019014267A1 (fr) | 2017-07-11 | 2019-01-17 | Synthorx, Inc. | Incorporation de nucléotides non naturels et procédés associés |
AU2018309172B2 (en) | 2017-08-03 | 2022-12-15 | Synthorx, Inc. | Cytokine conjugates for the treatment of autoimmune diseases |
CA3082383A1 (fr) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Anticorps bispecifiques et monospecifiques utilisant de nouvelles sequences anti-pd-1 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018372167B2 (en) | 2017-11-21 | 2023-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
EP3733716A4 (fr) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | Protéine de fusion dimère utilisant une région fc d'anticorps en tant que squelette et utilisation associée |
KR20200128533A (ko) | 2018-02-05 | 2020-11-13 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
JP7515412B2 (ja) * | 2018-03-09 | 2024-07-12 | アスクジーン・ファーマ・インコーポレイテッド | 新規のサイトカインプロドラッグ |
CA3094112A1 (fr) * | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Proteines de fusion de l'interleukine-2/du recepteur alpha de l'interleukine-2 et procedes d'utilisation |
MX2020009857A (es) * | 2018-03-28 | 2021-01-08 | Ascendis Pharma Oncology Div A/S | Conjugados de interleucina-2 (il-2). |
EP3773911A2 (fr) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes |
JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質 |
MX2020010910A (es) | 2018-04-18 | 2021-02-09 | Xencor Inc | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
JP7550745B2 (ja) * | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Il2アゴニスト |
EP3829605A4 (fr) * | 2018-08-01 | 2022-10-19 | ImmunityBio, Inc. | Système quadricistronique comprenant un récepteur de domiciliation ou une cytokine, et récepteur antigénique chimérique pour la modification génétique d'immunothérapies |
DK3849614T3 (da) * | 2018-09-11 | 2024-02-26 | Ambrx Inc | Interleukin-2-polypeptidkonjugater og anvendelser deraf |
WO2020060122A1 (fr) | 2018-09-17 | 2020-03-26 | (주)지아이이노베이션 | Protéine de fusion comprenant une protéine il-2 et une protéine cd80 et utilisation associée |
AR114732A1 (es) | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
JP7512210B2 (ja) * | 2018-09-21 | 2024-07-08 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規インターロイキン2およびその使用 |
JP2022501009A (ja) * | 2018-09-21 | 2022-01-06 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規インターロイキン2およびその使用 |
BR112021005907A2 (pt) * | 2018-09-27 | 2021-08-10 | Xilio Development, Inc. | citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
JP2022505871A (ja) * | 2018-10-23 | 2022-01-14 | ドラゴンフライ セラピューティクス, インコーポレイテッド | ヘテロ二量体fc融合タンパク質 |
MX2021004916A (es) * | 2018-10-29 | 2021-06-18 | 1Globe Biomedical Co Ltd | Nuevas composiciones proteicas de diseño idóneo. |
TW202034945A (zh) * | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
SG11202105093RA (en) | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
WO2020127369A1 (fr) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Molécule bifonctionnelle dirigée contre le pd-1 humain |
KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
AU2020206672A1 (en) * | 2019-01-07 | 2021-07-15 | Inhibrx Biosciences, Inc. | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
WO2020148612A1 (fr) * | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Virus de la vaccine recombinant et ses procédés d'utilisation |
EP3923974A4 (fr) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
EP3930850A1 (fr) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Anticorps hétérodimères qui se lient à enpp3 et cd3 |
CN111647068A (zh) * | 2019-03-04 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
CN111944008A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种突变蛋白的方法以及得到的突变体蛋白 |
CN111944036B (zh) * | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
WO2020234387A1 (fr) | 2019-05-20 | 2020-11-26 | Cytune Pharma | Schémas posologiques d'agonistes du récepteur il-2/il-15rssy pour traiter le cancer ou les maladies infectieuses |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
CA3141626A1 (fr) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Nouveaux promedicaments d'il-15 et leurs procedes d'utilisation |
KR20220035122A (ko) * | 2019-06-14 | 2022-03-21 | 큐진 인크. | 신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자 |
BR112021025130A2 (pt) | 2019-06-14 | 2022-03-15 | Scripps Research Inst | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
EP3994169A1 (fr) | 2019-07-02 | 2022-05-11 | F. Hoffmann-La Roche AG | Immunoconjugués comprenant une interleukine-2 mutante et un anticorps anti-cd8 |
BR112022001415A2 (pt) | 2019-07-26 | 2022-06-07 | Visterra Inc | Agentes interleucina-2 e os usos dos mesmos |
WO2021030483A1 (fr) * | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Protéines de fusion il-2 se liant de manière préférentielle à il-2 ralpha |
US20230203119A1 (en) | 2019-08-15 | 2023-06-29 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
WO2021055568A1 (fr) * | 2019-09-19 | 2021-03-25 | Proviva Therapeutics (Hong Kong) Limited | Compositions d'il-2 et leurs procédés d'utilisation |
US20220340621A1 (en) | 2019-09-27 | 2022-10-27 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
BR112022008129A2 (pt) | 2019-11-20 | 2022-08-23 | Gi Cell Inc | Composição da cultura de células t reguladoras e uso da mesma |
WO2021101271A1 (fr) | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | Composition de milieu pour la culture de lymphocytes t et procédé pour la culture de lymphocytes t l'utilisant |
JP7381750B2 (ja) | 2019-11-20 | 2023-11-15 | ジーアイ・セル・インコーポレイテッド | ナチュラルキラー細胞培養用組成物及びこれを用いたナチュラルキラー細胞の製造方法 |
BR112022010246A2 (pt) | 2019-11-27 | 2022-09-06 | Gi Innovation Inc | Composição farmacêutica para o tratamento de câncer compreendendo proteína de fusão compreendendo proteína il-2 e proteína cd80 e inibidor de checkpoint imunológico |
JP7488337B2 (ja) | 2019-11-27 | 2024-05-21 | ジーアイ・セル・インコーポレイテッド | Il-2タンパク質及びcd80タンパク質を含む融合タンパク質及びnk細胞を含む抗癌治療用組成物 |
KR20220114595A (ko) | 2019-12-17 | 2022-08-17 | 암젠 인크 | 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제 |
CN114524873A (zh) * | 2019-12-17 | 2022-05-24 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
JP2023510115A (ja) | 2019-12-20 | 2023-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規il2アゴニストおよびそれらの使用方法 |
CN115175690A (zh) * | 2020-01-09 | 2022-10-11 | 辉瑞大药厂 | 重组牛痘病毒 |
EP4087865A2 (fr) | 2020-01-10 | 2022-11-16 | Bright Peak Therapeutics AG | Polypeptides il-2 modifiés et leurs utilisations |
MX2022008772A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Ortologos de il2 y metodos de uso. |
JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型il2ムテイン、方法、および組成物 |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
WO2021168079A1 (fr) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Immunotolérance ciblée sur un tissu avec un effecteur cd39 |
TWI839476B (zh) * | 2020-02-26 | 2024-04-21 | 大陸商北京泰德製藥股份有限公司 | 介白素-2多肽共軛物及其用途 |
MX2022011154A (es) | 2020-03-18 | 2022-10-13 | Gi Innovation Inc | Composicion farmaceutica para el tratamiento de cancer que comprende proteina de fusion que se compone de proteina il-2 y proteina cd80 y farmaco anticancerigeno. |
EP4122447A4 (fr) | 2020-03-18 | 2023-11-01 | GI Innovation, Inc. | Préparation de protéine de fusion comprenant des protéines il-2 et cd80 |
US20230139890A1 (en) | 2020-03-18 | 2023-05-04 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof |
WO2021185362A1 (fr) | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | Mutant de l'interleukine-2 et son utilisation |
EP4122952A4 (fr) * | 2020-03-19 | 2024-05-29 | Innovent Biologics (Singapore) Pte. Ltd. | Mutant de l'interleukine-2 et son utilisation |
AU2021245922A1 (en) * | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-2 cytokines and their cleavage products |
WO2021209402A2 (fr) | 2020-04-15 | 2021-10-21 | F. Hoffmann-La Roche Ag | Immunoconjugués |
CA3168737A1 (fr) | 2020-04-21 | 2021-10-28 | Jiaxi WU | Variants de l'il-2 presentant une liaison reduite au recepteur alpha de l'il-2 et ses utilisations |
CN115916811A (zh) | 2020-04-22 | 2023-04-04 | 默沙东有限责任公司 | 偏向于白介素-2受体βγc二聚体并缀合非肽水溶性聚合物的人白介素-2缀合物 |
AU2021272340A1 (en) | 2020-05-11 | 2022-12-08 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
WO2021231773A1 (fr) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions de complexes protéiques et leurs méthodes d'utilisation |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
BR112022022826A2 (pt) | 2020-06-03 | 2022-12-13 | Ascendis Pharma Oncology Div A/S | Sequências de il-2 e usos das mesmas |
KR102373965B1 (ko) | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
CN115916827A (zh) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 免疫活化Fc结构域结合分子 |
CN115916831A (zh) | 2020-06-30 | 2023-04-04 | Gi 医诺微新 | 包含抗lag-3抗体和il-2的融合蛋白及其用途 |
KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법 |
TW202221031A (zh) | 2020-07-30 | 2022-06-01 | 英商阿法克塔生命科學有限公司 | 血清半衰期延長之pd-l1抑制多肽 |
MX2023001962A (es) | 2020-08-19 | 2023-04-26 | Xencor Inc | Composiciones anti-cd28. |
EP4211149A4 (fr) | 2020-09-09 | 2024-10-09 | Cue Biopharma Inc | Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation |
WO2022059794A1 (fr) * | 2020-09-18 | 2022-03-24 | 地方独立行政法人 宮城県立病院機構 | Protéine mutante d'il-2 et médicament la contenant |
CN118598977A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
CN114369153A (zh) * | 2020-10-18 | 2022-04-19 | 北京志道生物科技有限公司 | 一种白介素-2突变体 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022090203A1 (fr) | 2020-10-26 | 2022-05-05 | Cytune Pharma | AGONISTE IL-2/IL-15RβҮ POUR TRAITER LE CARCINOME MALPIGHIEN |
EP4232068A1 (fr) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Agoniste d'il-2/il-15r?? pour le traitement du cancer de la peau non mélanome |
EP4236962A1 (fr) | 2020-10-29 | 2023-09-06 | Bristol-Myers Squibb Company | Protéines de fusion pour le traitement d'une maladie |
CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
US20230398183A1 (en) | 2020-11-13 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
CN112724259B (zh) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
JP2023551563A (ja) | 2020-12-04 | 2023-12-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | pH依存性変異体インターロイキン-2ポリペプチド |
JP2024502708A (ja) | 2020-12-04 | 2024-01-23 | ビステラ, インコーポレイテッド | インターロイキン-2作用物質を使用する方法 |
WO2022148853A1 (fr) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugués |
CA3207261A1 (fr) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Compositions de therapie oncolytique par senecavirus armes et methodes associees |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4304724A1 (fr) | 2021-03-09 | 2024-01-17 | F. Hoffmann-La Roche AG | Polythérapie à base d'un immunoconjugué variant d'il-2 ciblant pd-1 et d'anticorps bispécifiques anti-tyrp1/anti-cd3 |
KR20230156051A (ko) | 2021-03-09 | 2023-11-13 | 에프. 호프만-라 로슈 아게 | Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법 |
EP4305065A1 (fr) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
EP4314032A1 (fr) | 2021-03-30 | 2024-02-07 | F. Hoffmann-La Roche AG | Polypeptides activés par une protéase |
US20240182571A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
CN113321722A (zh) * | 2021-04-13 | 2021-08-31 | 苏州复融生物技术有限公司 | 白介素2突变体及其应用 |
MX2023014647A (es) | 2021-06-09 | 2024-01-31 | Innate Pharma | Proteinas de union a nkp46 multiespecificas. |
WO2022258678A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a |
IL308531A (en) | 2021-06-09 | 2024-01-01 | Innate Pharma | Multiple specific antibodies that bind to CD20, NKP46, CD16 and are equipped with IL-2 |
WO2022258691A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a |
WO2022266467A2 (fr) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Polypeptide d'histone recombiné et ses utilisations |
AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
WO2023281481A1 (fr) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics | Conjugués d'anticorps et leur fabrication |
KR20240041379A (ko) | 2021-07-09 | 2024-03-29 | 브라이트 피크 테라퓨틱스 아게 | Il-2에 접합된 체크포인트 억제제 및 이의 용도 |
US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
WO2023017191A1 (fr) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Combinaison d'agonistes de l'il-2/il-15rbetagamma avec des conjugués anticorps-médicament pour le traitement du cancer |
MX2024002261A (es) | 2021-08-24 | 2024-03-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molecula de union de fap/cd40 y uso medicinal de la misma. |
KR20240067081A (ko) * | 2021-09-26 | 2024-05-16 | 우시 바이올로직스 아일랜드 리미티드 | Il-2 변이체 및 이의 융합 단백질 |
KR20240082349A (ko) | 2021-10-14 | 2024-06-10 | 에프. 호프만-라 로슈 아게 | 새로운 인터루킨-7 면역접합체 |
EP4429706A1 (fr) | 2021-10-14 | 2024-09-18 | F. Hoffmann-La Roche AG | Immunoconjugués de pd1-il7v alternatifs pour le traitement du cancer |
CU20210104A7 (es) | 2021-12-21 | 2023-07-12 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 |
KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
WO2023133595A2 (fr) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés |
US20230303650A1 (en) * | 2022-01-21 | 2023-09-28 | Aetio Biotherapy, Inc. | Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies |
WO2023161857A1 (fr) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Compositions de cytokine bifonctionnelle |
WO2023193015A1 (fr) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral |
US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
TW202409069A (zh) * | 2022-07-01 | 2024-03-01 | 大陸商北京星奇原生物科技有限公司 | Il-2多肽和使用方法 |
US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
TW202413398A (zh) * | 2022-08-16 | 2024-04-01 | 國立陽明交通大學 | 介白素-2變異體及其於治療癌症的用途 |
WO2024068705A1 (fr) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Polypeptides activés par une protéase |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
WO2024119193A2 (fr) | 2022-12-02 | 2024-06-06 | AskGene Pharma, Inc. | Polypeptides d'il-2 mutants et promédicaments d'il-2 |
WO2024150175A1 (fr) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Protéines activées de manière conditionnelle et procédés d'utilisation |
WO2024150174A1 (fr) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Immunocytokines activées de manière conditionnelle et procédés d'utilisation |
WO2024153722A1 (fr) | 2023-01-20 | 2024-07-25 | F. Hoffmann-La Roche Ag | Immunoconjugués |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
WO1987000056A1 (fr) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilisation de proteines pour des compositions pharmaceutiques utilisant une conjugaison de polymeres |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
CA2372813A1 (fr) | 1992-02-06 | 1993-08-19 | L.L. Houston | Proteine fixatrice biosynthetique pour marqueur du cancer |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19607751A1 (de) | 1996-02-29 | 1997-09-04 | Henkel Kgaa | Neue Aminophenol-Derivate und deren Verwendung |
JP2001504326A (ja) | 1996-10-18 | 2001-04-03 | ジェネンテック インコーポレーテッド | 抗ErbB2抗体 |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
EP0953639A1 (fr) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | Anticorps dirigé contre FAPalpha pouvant être produit avec une efficacité accrue |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
RU2236251C2 (ru) | 1999-02-12 | 2004-09-20 | Дзе Скриппс Рисерч Инститьют | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии |
NZ517906A (en) | 1999-10-04 | 2003-01-31 | Medicago Inc | Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001068708A2 (fr) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) |
JP4936299B2 (ja) | 2000-08-21 | 2012-05-23 | メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ | 磁場方向検出センサ |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
KR100927670B1 (ko) | 2001-04-13 | 2009-11-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Vla-1에 대한 항체들 |
AU2002355955A1 (en) | 2001-08-13 | 2003-03-03 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
WO2003048334A2 (fr) * | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines a selectivite modulee |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
ATE471946T1 (de) * | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
ES2542885T3 (es) | 2003-01-22 | 2015-08-12 | Roche Glycart Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2005062929A2 (fr) | 2003-12-22 | 2005-07-14 | Chiron Coporation | Utilisation des polymorphismes du recepteur fc comme diagnostic pour des strategies de traitement des troubles de la reponse immunitaire |
KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
WO2005097832A2 (fr) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Anticorps anti-tgf-$g(b) humanises |
US8455625B2 (en) | 2005-05-11 | 2013-06-04 | Philogen S.P.A. | Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12 |
EP1806365A1 (fr) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués |
EP2016098B1 (fr) | 2006-05-08 | 2016-09-07 | Philogen S.p.A. | Cytokines ciblees par des anticorps pour therapie |
WO2008003473A2 (fr) * | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions et procédés destinés à améliorer l'efficacité de réponses immunitaires à médiation par il-2 |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
PL2066796T3 (pl) | 2006-09-20 | 2011-11-30 | Mt Biomethan Gmbh | Sposób i urządzenie do separacji metanu i dwutlenku węgla z biogazu |
EP2120998B1 (fr) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements |
WO2009126558A1 (fr) | 2008-04-10 | 2009-10-15 | Ibc Pharmaceuticals, Inc. | Procédé modulaire pour préparer des cytokines tétramères avec une pharmacocinétique améliorée par la technologie « dock-and-lock » (dnl) |
BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
US8119130B2 (en) | 2007-07-25 | 2012-02-21 | Medimmune Limited | Targeted binding agents directed to KDR and uses thereof—035 |
EP2018877A1 (fr) | 2007-07-27 | 2009-01-28 | The Procter and Gamble Company | Article absorbant comprenant des particules polymériques absorbant l'eau et leur procédé de production |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
CA2723823C (fr) | 2008-05-13 | 2012-10-16 | Molmed S.P.A. | Conjugues pour le traitement du mesotheliome |
CA2749539C (fr) * | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions et methodes comprenant des mutants d'interleukine-2 destinees au traitement de maladies inflammatoires et auto-immunes |
WO2010088444A1 (fr) | 2009-01-29 | 2010-08-05 | Medimmune, Llc | Anticorps humains anti-il-6 à demi-vie prolongée in vivo et leur utilisation en oncologie et pour le traitement de maladies autoimmunes et inflammatoires |
CA2756393C (fr) * | 2009-03-24 | 2017-06-20 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anticorps anti-mesotheline |
WO2010117448A2 (fr) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Immunocytokines chimériques et leurs procédés d'utilisation |
US20120107270A1 (en) | 2009-06-30 | 2012-05-03 | Manuela Kaspar | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer |
WO2011020783A2 (fr) | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Immunoconjugués ciblés |
KR101528013B1 (ko) | 2009-08-31 | 2015-06-16 | 로슈 글리카트 아게 | 친화성-성숙된 인간화된 항-cea 단일클론 항체 |
DK2483310T3 (da) | 2009-09-29 | 2014-09-01 | Roche Glycart Ag | Bispecifik dødsreceptor-agonistiske antistoffer |
NZ703653A (en) | 2010-08-13 | 2016-09-30 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
UA117294C2 (uk) | 2011-02-10 | 2018-07-10 | Рош Глікарт Аг | Імунокон'югат |
KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
SG10201800535XA (en) | 2012-08-07 | 2018-02-27 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
WO2014023673A1 (fr) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Protéines de fusion de l'interleukine-10 et leurs utilisations |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
MX2015014538A (es) | 2013-05-07 | 2016-02-05 | Hoffmann La Roche | Moleculas de union a antigenos trimericas. |
KR102058846B1 (ko) | 2014-08-29 | 2020-02-20 | 에프. 호프만-라 로슈 아게 | 종양-표적 il-2 변이체 면역사이토카인 및 인간 pd-l1에 대한 항체의 조합 요법 |
-
2012
- 2012-02-07 UA UAA201611547A patent/UA117294C2/uk unknown
- 2012-02-07 US US13/367,843 patent/US9266938B2/en active Active
- 2012-02-07 SI SI201231430T patent/SI3075745T1/sl unknown
- 2012-02-07 PT PT16164244T patent/PT3075745T/pt unknown
- 2012-02-07 EP EP12702045.1A patent/EP2673294B1/fr active Active
- 2012-02-07 WO PCT/EP2012/051991 patent/WO2012107417A1/fr active Application Filing
- 2012-02-07 ES ES12702045.1T patent/ES2579987T3/es active Active
- 2012-02-07 HU HUE12702045A patent/HUE029139T2/hu unknown
- 2012-02-07 PL PL16164244T patent/PL3075745T3/pl unknown
- 2012-02-07 PE PE2013001855A patent/PE20140303A1/es active IP Right Grant
- 2012-02-07 RS RS20210996A patent/RS62238B1/sr unknown
- 2012-02-07 CN CN202010954354.5A patent/CN112210000A/zh active Pending
- 2012-02-07 DK DK18191941.6T patent/DK3489255T3/da active
- 2012-02-07 SI SI201230620A patent/SI2673294T1/sl unknown
- 2012-02-07 SG SG10201604160WA patent/SG10201604160WA/en unknown
- 2012-02-07 MX MX2013009226A patent/MX340671B/es active IP Right Grant
- 2012-02-07 CA CA2824253A patent/CA2824253C/fr active Active
- 2012-02-07 JP JP2013552930A patent/JP5878182B2/ja active Active
- 2012-02-07 BR BR112013018932-0A patent/BR112013018932B1/pt active IP Right Grant
- 2012-02-07 PL PL18191941T patent/PL3489255T3/pl unknown
- 2012-02-07 TW TW106101987A patent/TWI666027B/zh not_active IP Right Cessation
- 2012-02-07 MX MX2016006214A patent/MX356675B/es unknown
- 2012-02-07 DK DK16164244.2T patent/DK3075745T3/en active
- 2012-02-07 UA UAA201310726A patent/UA113729C2/uk unknown
- 2012-02-07 LT LTEP16164244.2T patent/LT3075745T/lt unknown
- 2012-02-07 LT LTEP18191941.6T patent/LT3489255T/lt unknown
- 2012-02-07 HU HUE16164244A patent/HUE040326T2/hu unknown
- 2012-02-07 PT PT181919416T patent/PT3489255T/pt unknown
- 2012-02-07 MY MYPI2013701387A patent/MY190604A/en unknown
- 2012-02-07 SI SI201231940T patent/SI3489255T1/sl unknown
- 2012-02-07 TW TW101103928A patent/TWI577801B/zh active
- 2012-02-07 CN CN201510970941.2A patent/CN105440123B/zh active Active
- 2012-02-07 IL IL269687A patent/IL269687B/en unknown
- 2012-02-07 ES ES18191941T patent/ES2883371T3/es active Active
- 2012-02-07 PT PT127020451T patent/PT2673294T/pt unknown
- 2012-02-07 SG SG2013060207A patent/SG192673A1/en unknown
- 2012-02-07 EA EA201300896A patent/EA033369B1/ru not_active IP Right Cessation
- 2012-02-07 EP EP18191941.6A patent/EP3489255B1/fr active Active
- 2012-02-07 CN CN201280017730.1A patent/CN103492411B/zh active Active
- 2012-02-07 RS RS20160397A patent/RS54802B1/sr unknown
- 2012-02-07 EP EP16164244.2A patent/EP3075745B1/fr active Active
- 2012-02-07 KR KR1020137020938A patent/KR101667096B1/ko active IP Right Grant
- 2012-02-07 EP EP21178401.2A patent/EP3971206A1/fr not_active Withdrawn
- 2012-02-07 PE PE2018000181A patent/PE20181077A1/es unknown
- 2012-02-07 KR KR1020157020539A patent/KR101852245B1/ko active IP Right Grant
- 2012-02-07 RS RS20181250A patent/RS57767B1/sr unknown
- 2012-02-07 PL PL12702045.1T patent/PL2673294T3/pl unknown
- 2012-02-07 HU HUE18191941A patent/HUE055284T2/hu unknown
- 2012-02-07 DK DK12702045.1T patent/DK2673294T3/en active
- 2012-02-07 ES ES16164244.2T patent/ES2694564T3/es active Active
- 2012-02-07 AU AU2012215573A patent/AU2012215573B2/en active Active
- 2012-02-08 AR ARP120100412A patent/AR085335A1/es active IP Right Grant
-
2013
- 2013-06-20 IL IL227095A patent/IL227095B/en active IP Right Grant
- 2013-06-24 CR CR20130314A patent/CR20130314A/es unknown
- 2013-06-25 CO CO13150839A patent/CO6741186A2/es unknown
- 2013-07-05 CL CL2013001987A patent/CL2013001987A1/es unknown
- 2013-07-12 ZA ZA2013/05282A patent/ZA201305282B/en unknown
- 2013-08-09 EC ECSP13012815 patent/ECSP13012815A/es unknown
- 2013-09-10 MA MA36237A patent/MA35803B1/fr unknown
-
2014
- 2014-03-27 HK HK16105003.6A patent/HK1217020A1/zh unknown
-
2015
- 2015-05-20 JP JP2015102866A patent/JP6155300B2/ja not_active Expired - Fee Related
- 2015-10-28 AU AU2015249085A patent/AU2015249085B2/en not_active Ceased
-
2016
- 2016-01-15 US US14/996,789 patent/US10323098B2/en active Active
- 2016-07-21 CY CY20161100718T patent/CY1117842T1/el unknown
- 2016-07-21 HR HRP20160917TT patent/HRP20160917T1/hr unknown
-
2017
- 2017-05-11 IL IL25223017A patent/IL252230B/en active IP Right Grant
- 2017-05-24 PH PH12017500954A patent/PH12017500954A1/en unknown
- 2017-12-20 US US15/849,501 patent/US10184009B2/en active Active
-
2018
- 2018-10-22 HR HRP20181736TT patent/HRP20181736T1/hr unknown
- 2018-11-21 US US16/198,531 patent/US11111312B2/en active Active
-
2019
- 2019-06-17 US US16/443,306 patent/US20190322765A1/en not_active Abandoned
-
2021
- 2021-08-16 HR HRP20211318TT patent/HRP20211318T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35803B1 (fr) | Polypeptides d'interleukine-2 mutants | |
PH12019502273A1 (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
EP2576578A4 (fr) | Formes polymorphiques du 2'-o-fucosyllactose et leurs procédés de production | |
SG164344A1 (en) | Immunogens from uropathogenic escherichia coli | |
WO2010034032A3 (fr) | Procédés pour préparer des compositions de polypeptide purifié | |
EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
MX2022001086A (es) | Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos. | |
AU2016204319A1 (en) | Methods and compositions for producing squalene using yeast | |
EP3444352A3 (fr) | Production d'un vaccin recombinant dans e. coli par conjugaison enzymatique | |
EP2586790A3 (fr) | Immunogènes d'Escherischia coli pathogènes des voies urinaires | |
MX2009001203A (es) | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. | |
EP4374919A3 (fr) | Méthodes de traitement de la dermatite atopique par administration d'un antagoniste de l'il-4r | |
MX2007008790A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso. | |
MX348823B (es) | Formulaciones estables de linaclotida. | |
MX2012001346A (es) | Polipeptidos del factor ix modificados y usos de los mismos. | |
MX2010005589A (es) | Composicion para el cuidado personal. | |
WO2022058591A3 (fr) | Nanocorps anti-sars-cov-2 | |
MA32291B1 (fr) | Utilisation d'un extrait de myrte comme dépigmentant | |
MA46819B1 (fr) | Streptococcus thermophilus pour utilisation dans la préparation de produits fermentés | |
RU2013100175A (ru) | Способ получения бессвинцового подшипника скольжения | |
WO2008140598A3 (fr) | Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci | |
GB201219259D0 (en) | Aluminum alloy bearing | |
MX2023006480A (es) | Polipeptidos de interleucina-2 mutante dependientes del ph. | |
IN2012DN06607A (fr) | ||
CR20240155A (es) | Nuevos inmunoconjugados de interleucina-7 |